Overview of current advances in and future approaches to CLL management with BTK and Bcl-2 inhibitors, with patient cases illustrating criteria for treatment selection and sequencing and reference to new guidelines.

Oral presentation at EHA2022 describing the potential for combination therapy with a Bruton's tyrosine kinase inhibitor (BTKi) and an anti-CD20 monoclonal antibody as a therapeutic option for relapsed/refractory (R/R) follicular lymphoma (FL).

Exploring the potential for a BTK protein degrader as a therapeutic option in patients with B-cell malignancies.